In vitro synergistic/additive activity of levofloxacin with meropenem against Stenotrophomonas maltophilia

Diagnostic Microbiology and Infectious Disease

Volumn 67, Issue 3, 2010, Pages 297-300

  Pankey, George A ^a   Ashcraft, Deborah S ^a  

^a OCHSNER CLINIC FOUNDATION   (United States)

Author keywords

Levofloxacin; Meropenem; Stenotrophomonas; Synergy

Indexed keywords

LEVOFLOXACIN; MEROPENEM;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG POTENTIATION; EPSILOMETER TEST; IN VITRO STUDY; INTERMETHOD COMPARISON; LABORATORY TEST; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STENOTROPHOMONAS MALTOPHILIA; TIME KILL ASSAY;

ANTI-BACTERIAL AGENTS; DRUG SYNERGISM; HUMANS; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; OFLOXACIN; STENOTROPHOMONAS MALTOPHILIA; THIENAMYCINS;

EID: 77953681047     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2010.02.015     Document Type: Article

References (16)

1. Alonso A., Martinez J.L. Multiple antibiotic resistance in Stenotrophomonas maltophilia. Antimicrob. Agents Chemother. 1997, 41:1140-1142.
2. Bonfiglio G., Cascone C., Azzarelli C., Cafiso V., Marchetti F., Stefani S. Levofloxacin in vitro activity and time-kill evaluation of Stenotrophomonas maltophilia clinical isolates. J. Antimicrob. Chemother. 2000, 45:115-117.
3. Clinical and Laboratory Standards Institute (CLSI) Performance standards for antimicrobial susceptibility testing; 19th informational supplement. CLSI document M100-S19 2009, CLSI, Wayne, PA.
4. Falagas M.E., Valkimadi P.E., Huang Y.T., Matthaiou D.K., Hsueh P.R. Therapeutic options for Stenotrophomonas maltophilia infections beyond co-trimoxazole: a systematic review. J. Antimicrob. Chemother. 2008, 62:889-894.
5. Falagas M.E., Kastoris A.C., Vouloumanou E.K., Rafailidis P.I., Kapaskelis A.M., Dimopoulos G. Attributable mortality of Stenotrophomonas maltophilia infections: a systematic review of the literature. Future Microbiol. 2009, 4:1103-1109.
6. Galles A.C., Jones R.N., Sader H.S. Antimicrobial susceptibility profile of contemporary clinical strains of Stenotrophomonas maltophilia isolates: can moxifloxacin activity be predicted by levofloxacin MIC results?. J. Chemother. 2008, 20:38-42.
7. Isenberg H.D., Alperstein P., France K. In vitro activity of ciprofloxacin, levofloxacin, and trovafloxacin, alone and in combination with beta-lactams, against clinical isolates of Pseudomonas aeruginosa, Stenotrophomonas maltophilia, and Burkholderia cepacia. Diagn. Microbiol. Infect. Dis. 1999, 33:81-86.
8. Looney W.J., Narita M., Muhlemann K. Stenotrophomonas maltophilia: an emerging opportunist human pathogen. Lancet Infect. Dis. 2009, 9:312-323.
9. Mendoza D.L., Darin M., Waterer G.W., Wunderink R.G. Update on Stenotrophomonas maltophilia infection in the ICU. Clin. Pulm. Med. 2007, 14:17-22.
10. National Committee for Clinical Laboratory Standards (NCCLS) Methods for determining bactericidal activity of antimicrobial agents; approved guideline. NCCLS document M26-A 1999, NCCLS, Wayne, PA.
11. Pankey G.A., Ashcraft D.S. In vitro synergy of ciprofloxacin and gatifloxacin against ciprofloxacin-resistant Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 2005, 49:2959-2964.
12. Passerini de Rossi B., García C., Calenda M., Vay C., Franco M. Activity of levofloxacin and ciprofloxacin on biofilms and planktonic cells of Stenotrophomonas maltophilia isolates from patients with device-associated infections. Int. J. Antimicrob. Agents 2009, 34:260-264.
13. Pillai S.K., Moellering R.C., Eliopoulos G.M. Antimicrobial combinations. Antibiotics in laboratory medicine 2005, 365-440. Lippincott Williams and Wilkins, Philadelphia, PA. 5th ed. V. Lorian (Ed.).
14. Sader H.S., Jones R.N. Antimicrobial susceptibility of uncommonly isolated non-enteric Gram-negative bacilli. Int. J. Antimicrob. Agents 2005, 25:95-109.
15. Toleman M.A., Bennett P.M., Bennett D.M.C., Jones R.N., Walsh T.R. Global emergence of trimethoprim/sulfamethoxazole resistance in Stenotrophomonas maltophilia mediated by acquisition of sul genes. Emerg. Infect. Dis. 2007, 13:559-564.
16. Zhang L., Li X.Z., Poole K. Multiple antibiotic resistance in Stenotrophomonas maltophilia: involvement of a multidrug efflux system. Antimicrob. Agents Chemother. 2000, 44:287-293.